Trial Profile

An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys and Viread and REP 2165-Mg in Combination With Pegasys and Viread in Patients With HBeAg Negative Chronic Hepatitis B

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REP 2139 (Primary) ; REP 2165 (Primary) ; Interferon alpha-2a; Tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Adverse reactions
Sponsors REPLICor

24 Jul 2023 According to Replicor media release, this study is part of an ongoing collaboration with Dr. Harel Dahari's team at Loyola University (Chicago, USA)
24 Jul 2023 According to Replicor media release, results from this trial were published in the Hepatology Communications.
24 Jul 2023 Results presented in the REPLICor Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com